# Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

> **NCT06113081** · — · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 100 (actual)

## Conditions studied

- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Cutaneous T-Cell Lymphoma/Sezary Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06113081
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-06
- **Primary completion:** 2025-10-10
- **Final completion:** 2025-11-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113081, "Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06113081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*